Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
ECDD Technical summary
4-Methoxyamphetamine (p-methoxyamphetamine, PMA) is a racemic mixture with a pharmacological profile that is predominantly amphetamine-like. It also shows some pharmacological activity resembling LSD (e.g., visual tracking in monkeys and dogs). From studies in man, this substance has been estimated to be five times more potent as a psychotomimetic than mescaline. In different studies of its dependence potential in rodents, the discriminative effect of 4-methoxyamphetamine was amphetaminelike or resembled LSD. It was not self-administered by baboons. No data are available from studies in man on the clinical abuse liability relevant to the dependence potential of this substance.
In isolated geographical areas, serious adverse reactions have been reported and fatal toxicity has appeared. The signs of intoxication include those observed with amphetamine and also with mescaline. Data on governmental seizures of the drug indicate only isolated cases of illicit trafficking in the substance. On the basis of the data outlined above, it was the consensus of the Expert Committee that 4-methoxyamphetamine met the criteria of article 2, paragraph 4, for control under the Convention on Psychotropic Substances. Since this substance has no therapeutic use, the Expert Committee recommended that it be placed in Schedule I of the Convention.
4-Methoxyamphetamine (p-methoxyamphetamine, PMA) is a racemic mixture with a pharmacological profile that is predominantly amphetamine-like. It also shows some pharmacological activity resembling LSD (e.g., visual tracking in monkeys and dogs). From studies in man, this substance has been estimated to be five times more potent as a psychotomimetic than mescaline. In different studies of its dependence potential in rodents, the discriminative effect of 4-methoxyamphetamine was amphetaminelike or resembled LSD. It was not self-administered by baboons. No data are available from studies in man on the clinical abuse liability relevant to the dependence potential of this substance.
In isolated geographical areas, serious adverse reactions have been reported and fatal toxicity has appeared. The signs of intoxication include those observed with amphetamine and also with mescaline. Data on governmental seizures of the drug indicate only isolated cases of illicit trafficking in the substance. On the basis of the data outlined above, it was the consensus of the Expert Committee that 4-methoxyamphetamine met the criteria of article 2, paragraph 4, for control under the Convention on Psychotropic Substances. Since this substance has no therapeutic use, the Expert Committee recommended that it be placed in Schedule I of the Convention.
ECDD Recommendation
Inclusion in Schedule I of the 1971 Convention on Psychotropic Substances
Link to full TRS
who_trs_729.pdf1.29 MB